- Home
- TD vs GILD Comparison
TD vs GILD Comparison
Compare TD & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TD
- GILD
- Stock Information
- Founded
- TD 1855
- GILD 1987
- Country
- TD Canada
- GILD United States
- Employees
- TD N/A
- GILD N/A
- Industry
- TD
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TD
- GILD Health Care
- Exchange
- TD Nasdaq
- GILD Nasdaq
- Market Cap
- TD 126.6B
- GILD 144.1B
- IPO Year
- TD N/A
- GILD 1992
- Fundamental
- Price
- TD $74.47
- GILD $115.05
- Analyst Decision
- TD Buy
- GILD Buy
- Analyst Count
- TD 2
- GILD 23
- Target Price
- TD $91.50
- GILD $115.68
- AVG Volume (30 Days)
- TD 1.9M
- GILD 5.9M
- Earning Date
- TD 08-28-2025
- GILD 11-05-2025
- Dividend Yield
- TD 4.00%
- GILD 2.75%
- EPS Growth
- TD 174.71
- GILD 496.80
- EPS
- TD 8.44
- GILD 5.01
- Revenue
- TD $45,838,361,213.00
- GILD $28,863,000,000.00
- Revenue This Year
- TD $10.85
- GILD $2.01
- Revenue Next Year
- TD $3.86
- GILD $4.03
- P/E Ratio
- TD $8.67
- GILD $22.96
- Revenue Growth
- TD 20.82
- GILD 3.81
- 52 Week Low
- TD $51.25
- GILD $77.74
- 52 Week High
- TD $78.95
- GILD $121.83
- Technical
- Relative Strength Index (RSI)
- TD 52.10
- GILD 52.20
- Support Level
- TD $72.73
- GILD $111.28
- Resistance Level
- TD $78.95
- GILD $118.13
- Average True Range (ATR)
- TD 1.33
- GILD 2.06
- MACD
- TD 0.01
- GILD -0.46
- Stochastic Oscillator
- TD 27.97
- GILD 39.23
About TD Toronto Dominion Bank (The)
Toronto-Dominion is one of Canada's two largest banks with over CAD 2 trillion in assets. TD Bank operates four business segments: Canadian personal and commercial banking, US retail banking, wealth management and insurance, and wholesale banking. The bank derives more than 55% of its revenue from Canada and has dominant market share in nearly all banking products and services. TD has around 40% of its revenue from its US operations. Its US footprint spans from Maine to Florida, with a strong presence in the Northeast.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).